The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The safety and feasibility of CAR-T & bispecifics in patients with myeloma after prior alloSCT
Binod Dhakal, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the findings of a study assessing the safety and feasibility of using novel immunotherapies, such as CAR-T and bispecific antibodies, in patients with multiple myeloma (MM) who have progressed following allogeneic stem cell transplantation (alloSCT). These immunotherapies led to deep and durable responses in patients without increasing the risk of adverse events (AEs). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
